With the structural (c17-AA) alteration, the tablets will place a higher level of stress on the liver than the injectable. During longer or higher dosed cycles, liver values should therefore be watched closely through regular blood work. Such stress would of course be amplified when adding other c17-AA oral compounds to a cycle of stanozolol. When using such combinations, cautious users would make every effort to limit the length of the cycle not to be longer than a maximum of 6-8 weeks. It is also of note that stanozolol has been linked to strong adverse changes in the cholesterol levels. This side effect is common with anabolic steroid therapy, and obviously can become a health concern as the dose/duration of intake increase above normal. The oral version should have a greater impact on cholesterol values than the injectable due to the method of administration, and may therefore be the worse choice of the two for those concerned of this side effect. The oral use of stanozolol can also have a profound impact on levels of SHBG (sex hormone-binding globulin). This is characteristic of all anabolic/androgenic steroids, however its potency and form of administration makes oral stanozolol particularly noteworthy in this regard. Since plasma binding proteins such as SHBG act to temporarily constrain steroid hormones from exerting activity, this effect would provide a greater percentage of free (unbound) steroid hormone in the body. This may amount to an effective mechanism in which stanozolol could increase the potency of a concurrently used steroid. Proviron has an extremely high affinity for SHBG. This affinity may cause Proviron to displace other weaker substrates for SHBG, another mechanism in which the free hormone level may be increased. Adding stanozolol and Proviron to a testosterone cycle may therefore prove very useful, markedly enhancing the free state of this potent muscle building androgen.
Dragon Pharmaceutical Inc. is an international biopharmaceutical corporation engaged in the discovery, development and commercialization of genetically engineered human proteins for therapeutic use. Based on its proprietary protein expression technology, Dragon believes that it has become one of the world’s most competitive producers of Erythropoietin (EPO) a breakthrough drug that has revolutionized the treatment of anemia. Dragon is also applying its platform technology to the development of other generic and novel protein drugs.